Datta Niloy R, Kumar Piyush, Singh Shalini, Gupta Dinesh, Srivastava Anurita, Dhole Tapankumar N
Department of Radiotherapy, Regional Cancer Centre, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Barelli Road, Lucknow-226014, India.
Gynecol Oncol. 2006 Oct;103(1):100-5. doi: 10.1016/j.ygyno.2006.01.058. Epub 2006 Mar 23.
To evaluate if pretreatment HPV titers in cancer cervix could predict radiation response and survival outcomes.
Twenty-one patients of cancer cervix were treated by radiotherapy (RT) alone. HPV titers were estimated using DNA Hybrid Capture II test. Loco-regional response at 1 month of RT--complete or partial response (CR and PR respectively) and survival outcomes--local disease-free (LDFS), disease-free (DFS) and overall (OS) survivals were evaluated against pre- and posttreatment HPV titers.
Pretreatment HPV titers ranged from 0.81 to 3966.10 RLU/cut off (mean +/- SD: 1264.39 +/- 1148.22, median: 1129.98). Of the demographic features evaluated, mean HPV titers were significantly different only for patients achieving CR or PR at completion of RT (mean +/- SD for CR vs. PR: 1616.31 +/- 1146.86 vs. 384.57 +/- 538.80, P = 0.022). HPV titers at end of RT ranged from 0.12 to 487.42 RLU/cut off (mean +/- SD: 37.31 +/- 108.60, median: 2.33). Patients with higher pretreatment HPV titers (>1000 RLU/cutoff) had a higher CR (P = 0.022) and better survival compared to those with < or =1000 RLU/cutoff (LDFS, P = 0.004; DFS, P = 0.005; OS, P = 0.012). At completion of RT, those having > or =99.5% fall in HPV had superior survival outcomes than those with <99.5% reduction (LDFS, P = 0.002; DFS, P = 0.002; OS, P = 0.004).
Higher pretreatment HPV titers (>1000 RLU/cutoff) could be considered as a predictor of radiotherapy response and survival in cancer cervix. A reduction in these titers to 99.5% of their baseline values at end of radiotherapy is also associated with better survival outcomes.
评估宫颈癌患者治疗前的人乳头瘤病毒（HPV）滴度是否可预测放疗反应及生存结局。
21例宫颈癌患者仅接受放射治疗（RT）。采用DNA杂交捕获II试验评估HPV滴度。根据治疗前和治疗后的HPV滴度评估放疗1个月时的局部区域反应——完全缓解或部分缓解（分别为CR和PR）以及生存结局——局部无病生存期（LDFS）、无病生存期（DFS）和总生存期（OS）。
治疗前HPV滴度范围为0.81至3966.10 RLU/临界值（均值±标准差：1264.39±1148.22，中位数：1129.98）。在所评估的人口统计学特征中，仅放疗结束时达到CR或PR的患者的平均HPV滴度存在显著差异（CR与PR的均值±标准差：1616.31±1146.86 vs. 384.57±538.80，P = 0.022）。放疗结束时HPV滴度范围为0.12至487.42 RLU/临界值（均值±标准差：37.31±108.60，中位数：2.33）。与治疗前HPV滴度≤1000 RLU/临界值的患者相比，治疗前HPV滴度＞1000 RLU/临界值的患者CR更高（P = 0.022）且生存情况更好（LDFS，P = 0.004；DFS，P = 0.005；OS，P = 0.012）。放疗结束时，HPV下降≥99.5%的患者的生存结局优于下降＜99.5%的患者（LDFS，P = 0.002；DFS，P = 0.002；OS，P = 0.004）。
较高的治疗前HPV滴度（＞1000 RLU/临界值）可被视为宫颈癌放疗反应和生存的预测指标。放疗结束时这些滴度降至其基线值的99.5%也与更好的生存结局相关。
